Investigation of Association between Plasminogen Activator Inhibitor Type-1 (<i>PAI-1</i>) Gene 4G/5G Polymorphism Frequency and Plasma PAI-1 Enzyme Activity in Patients with Acute Stroke

Kucukarabaci, Banu; Güneş, Hasan Veysi; Özdemir, Gazi; Coşan, Didem Turgut; Özbabalık, Demet; Dikmen, Miriş; Değirmenci, İrfan

doi:10.1089/gte.2008.0025

Cited by 11 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings are also consistent with that of a previous study conducted on the Turkish patients with stroke, showing genotype distribution for 4G as 51%, for 5G as 49%, and 49-51% in controls, respectively [16]. However, in a study with hypertension patients, 4G allel frequency was 31.25% and 5G allel frequency found 68.75%, and as for the control group, it was 49-51%, respectively.…”

Section: Discussionsupporting

confidence: 92%

Lack of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism and osteoarthritis

et al. 2011

View full text Add to dashboard Cite

This study was conducted in Turkish osteoarthritis patients to determine the frequency of 4G/5G polymorphism genotypes of plasminogen activator inhibitor type-1 gene and to examine the role of this polymorphism in osteoarthritis development. Genomic DNA obtained from 200 persons (140 patients with osteoarthritis and 60 healthy controls) was used in the study. DNA was amplified by polymerase chain reaction using 4G allele- and 5G allele-specific primers. Polymerase chain reaction products were assessed with CCD camera by being exposed to 2% agarose gel electrophoresis. No statistically significant difference between the groups with respect to genotype distribution was found (P > 0.05) in the study. The 4G allele frequency was indicated as 44% and 5G allele was as 56% in patients, whereas this was 45-55% in the control group. This study has established that 4G/5G polymorphism genotypes of plasminogen activator inhibitor type-1 gene do not play a role in the development of osteoarthritis in the Turkish population.

show abstract

Section: Discussionsupporting

confidence: 92%

Lack of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism and osteoarthritis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In the former studies related to the Turkish population, genotype percentages in the asthma group were found to be 26.5% for 4G4G, 43.9% for 4G5G, and 29.6% for 5G5G (Cosan et al, 2009) and for the stroke group, 45% for 4G4G, 12.3% for 4G5G, and 42.7% for 5G5G (Kucukarabaci et al, 2008). As no relation was found between such distribution and asthma, it was determined that 4G5G genotype has significantly decreased in the stroke group, compared with the control group.…”

Section: Discussionmentioning

confidence: 91%

Plasminogen Activator Inhibitor Type-1 Gene 4G/5G Polymorphism Is Associated with Hypertensive Patients in the Turkish Population

Güneş

Coşan²,

Ata³

et al. 2010

Genetic Testing and Molecular Biomarkers

Self Cite

View full text Add to dashboard Cite

This study has been performed on hypertensive patients in the Turkish population to determine the frequency of 4G/5G polymorphism genotypes of plasminogen activator inhibitor type-1 gene and with the aim of examining the role of this polymorphism in hypertension development. Genomic DNA obtained from 284 persons (176 patients with hypertension and 108 healthy controls) was used in the study. DNA was multiplied by polymerase chain reaction using 4G and 5G allele-specific primers. Polymerase chain reaction products were assessed by being exposed to 2% agarose gel electrophoresis. Results were evaluated with the chi-square test. The 4G allele frequency was 31.25% and the 5G allele frequency was 68.75% in patients, whereas it was 49/51% in a control group. 5G5G genotype was found statistically high (p < 0.001) in patients relative to controls. This study showed that the plasminogen activator inhibitor type-1 gene 4G/5G polymorphism and the 5G5G genotype appear to be associated with an elevated risk of developing hypertension in a representative sample of Turkish population.

show abstract

“…Higher levels of PAI-1 at the inflammatory site in association with pronounced airway remodelling may, therefore, lead to a lower lung function. The 4G/5G polymorphism directly influences the level and activity of PAI-1 in plasma, and individuals with the 4G allele have higher plasma PAI-1 levels and activity [20,21,38,39]. Differences in PAI-1 levels between the genotypes can therefore be involved in the development and progression of asthma.…”

Section: Discussionmentioning

confidence: 99%

“…Unfortunately, we have no data on serum PAI-1 levels and are thus unable to confirm higher PAI-1 levels in individuals with the 4G allele. Although some studies have described higher PAI-1 plasma levels to be associated with the 4G allele [20,21,38,39], this has not been invariably shown [12,40]. Moreover, STEVENS et al [41] showed that PAI-1 expression and activity was increased in epithelial brushings of children with asthma, which was not reflected in plasma.…”

Section: Discussionmentioning

confidence: 99%

SERPINE1 -675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response

Dijkstra¹,

Postma

Bruinenberg³

et al. 2011

European Respiratory Journal

View full text Add to dashboard Cite

Asthma is characterised by chronic airway inflammation and remodelling, which can be (partially) suppressed by inhaled corticosteroids (ICSs). Plasminogen activator inhibitor-1, encoded by the SERPINE1 gene, is the key inhibitor of the plasminogen activator system, which affects tissue repair and remodelling.We studied associations between a functional SERPINE1 -675 4G/5G promoter polymorphism and asthma development, severity and response to ICSs.Longitudinal cohorts of 281 asthmatics and their nonasthmatic spouses, and the general population (n51,390) were studied. No significant associations were found with asthma development and immunoglobulin (Ig)E levels, or with forced expiratory volume in 1 s (FEV1) in nonasthmatic controls. Asthmatic subjects carrying the SERPINE1 5G allele had higher IgE and lower lung function levels at follow-up, lower maximally attained lung function levels, and faster lung function decline compared with individuals with the 4G/4G genotype. ICS treatment showed an immediate improvement in FEV1 in asthmatics carrying the 5G allele. However, these asthmatics still had the fastest rate of FEV1 decline after initiating ICS treatment. Finally, the 5G allele was associated with a lower prevalence of complete asthma remission at follow-up.These findings suggest that SERPINE1 is not an asthma susceptibility gene, but rather affects the severity, progression and long-term ICS response in asthma.

show abstract

Investigation of Association between Plasminogen Activator Inhibitor Type-1 (PAI-1) Gene 4G/5G Polymorphism Frequency and Plasma PAI-1 Enzyme Activity in Patients with Acute Stroke

Cited by 11 publications

References 26 publications

Lack of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism and osteoarthritis

Lack of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism and osteoarthritis

Plasminogen Activator Inhibitor Type-1 Gene 4G/5G Polymorphism Is Associated with Hypertensive Patients in the Turkish Population

SERPINE1 -675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response

Contact Info

Product

Resources

About